Recent Biotech Reverse Mergers Accelerate BTK‑Based Immune & Inflammatory Drug Programs on July 30, 2026 BTK inhibitor Caldera Therapeutics civorebrutinib I&I Immune Inflammatory Processa Pharmaceuticals reverse merger Synlogic +
Travere pays Everest $112.5M upfront to grow rare kidney disease pipeline on June 03, 2026 civorebrutinib Everest Everest Medicines Infrequent Kidney Diseases licensing agreement milestone payments royalties Travere +